166 related articles for article (PubMed ID: 37996645)
1. Antibiotic-associated vanishing bile duct syndrome: a real-world retrospective and pharmacovigilance database analysis.
Wang J; Wang S; Wu C; Deng Z
Infection; 2024 Jun; 52(3):891-899. PubMed ID: 37996645
[TBL] [Abstract][Full Text] [Related]
2. Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Patek TM; Teng C; Kennedy KE; Alvarez CA; Frei CR
Drug Saf; 2020 Jan; 43(1):17-22. PubMed ID: 31691256
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Teng C; Baus C; Wilson JP; Frei CR
Int J Med Sci; 2019; 16(11):1504-1509. PubMed ID: 31673242
[No Abstract] [Full Text] [Related]
4. Meropenem-induced vanishing bile duct syndrome.
Schumaker AL; Okulicz JF
Pharmacotherapy; 2010 Sep; 30(9):953. PubMed ID: 20812433
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis.
Nguyen KD; Tran TN; Nguyen MT; Nguyen HA; Nguyen HA; Vu DH; Nguyen VD; Bagheri H
J Clin Pharm Ther; 2019 Feb; 44(1):69-77. PubMed ID: 30129156
[TBL] [Abstract][Full Text] [Related]
6. Acute vanishing bile duct syndrome after therapy with cephalosporin, metronidazole, and clotrimazole: A case report.
Zhao Z; Bao L; Yu X; Zhu C; Xu J; Wang Y; Yin M; Li Y; Li W
Medicine (Baltimore); 2017 Sep; 96(36):e8009. PubMed ID: 28885366
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.
Borrelli EP; Lee EY; Descoteaux AM; Kogut SJ; Caffrey AR
Epilepsia; 2018 Dec; 59(12):2318-2324. PubMed ID: 30395352
[TBL] [Abstract][Full Text] [Related]
8. Rhabdomyolysis associated with newer-generation anti-seizure medications (ASMs): a real-world retrospective and pharmacovigilance study.
Deng Z; Wang S; Wu C
Front Pharmacol; 2023; 14():1197470. PubMed ID: 37849732
[No Abstract] [Full Text] [Related]
9. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Teng C; Walter EA; Gaspar DKS; Obodozie-Ofoegbu OO; Frei CR
Int J Med Sci; 2019; 16(7):1018-1022. PubMed ID: 31341415
[No Abstract] [Full Text] [Related]
10. Colistin-associated Stevens-Johnson syndrome and toxic epidermal necrolysis reactions: a retrospective case-non-case pharmacovigilance study.
Tang R; Lopes VL; Caffrey AR
Expert Opin Drug Saf; 2022 Aug; 21(8):1121-1126. PubMed ID: 35196183
[TBL] [Abstract][Full Text] [Related]
11. Vanishing bile duct syndrome in a child with toxic epidermal necrolysis: an interplay of unbalanced immune regulatory mechanisms.
Karnsakul W; Arkachaisri T; Atisook K; Wisuthsarewong W; Sattawatthamrong Y; Aanpreung P
Ann Hepatol; 2006; 5(2):116-9. PubMed ID: 16807519
[TBL] [Abstract][Full Text] [Related]
12. Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man.
Juricic D; Hrstic I; Radic D; Skegro M; Coric M; Vucelic B; Francetic I
Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):62-5. PubMed ID: 19906050
[TBL] [Abstract][Full Text] [Related]
13. Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database.
Lebrun-Vignes B; Guy C; Jean-Pastor MJ; Gras-Champel V; Zenut M;
Br J Clin Pharmacol; 2018 Feb; 84(2):331-338. PubMed ID: 28963996
[TBL] [Abstract][Full Text] [Related]
14. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.
Bonkovsky HL; Kleiner DE; Gu J; Odin JA; Russo MW; Navarro VM; Fontana RJ; Ghabril MS; Barnhart H; Hoofnagle JH;
Hepatology; 2017 Apr; 65(4):1267-1277. PubMed ID: 27981596
[TBL] [Abstract][Full Text] [Related]
15. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
[TBL] [Abstract][Full Text] [Related]
16. Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.
Okan G; Yaylaci S; Peker O; Kaymakoglu S; Saruc M
World J Gastroenterol; 2008 Aug; 14(29):4697-700. PubMed ID: 18698687
[TBL] [Abstract][Full Text] [Related]
17. Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis.
White JC; Appleman S
Pediatrics; 2014 Oct; 134(4):e1194-8. PubMed ID: 25246624
[TBL] [Abstract][Full Text] [Related]
18. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
[TBL] [Abstract][Full Text] [Related]
19. Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System.
Zhao D; Long X; Wang J
Expert Opin Drug Saf; 2024 May; 23(5):599-605. PubMed ID: 38553867
[TBL] [Abstract][Full Text] [Related]
20. Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated With Antibiotic Use: A Case-Crossover Study.
Fukasawa T; Urushihara H; Takahashi H; Okura T; Kawakami K
J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3463-3472. PubMed ID: 37459954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
